ATX-304 is a small molecule, combined AMPK and mitochondrial activator for cardiometabolic diseases. It is currently being studied in a Phase 1B trial in pre-diabetic, overweight / obese subjects in the European Union. In pre-clinical studies, ATX-304 demonstrated beneficial effects on glucose and lipid metabolism and energy expenditure in multiple animal models of obesity and metabolic disease, as well as on cardiovascular function and exercise endurance in aging and aged animals. Upon completion of the Phase 1B study, the Amplifier team is considering further development of ATX-304 for chronic weight management in adult patients with overweight/obesity and associated cardiometabolic disorders.

ATX-304 is a small molecule, combined AMPK and mitochondrial activator for cardiometabolic diseases. It is currently being studied in a Phase 1B trial in pre-diabetic, overweight / obese subjects in the European Union. In pre-clinical studies, ATX-304 demonstrated beneficial effects on glucose and lipid metabolism and energy expenditure in multiple animal models of obesity and metabolic disease, as well as on cardiovascular function and exercise endurance in aging and aged animals. Upon completion of the Phase 1B study, the Amplifier team is considering further development of ATX-304 for chronic weight management in adult patients with overweight/obesity and associated cardiometabolic disorders.

‍

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

‍

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

‍

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

‍

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

‍

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

‍

Telovance™ is a protein complex that is delivered during the ex-vivo expansion stage of cell manufacturing. Telovance™ is designed to enhance the next generation of cell therapies and enable more sophisticated, multi-step cell engineering technologies.